Accredo Health Group selected as sole specialty pharmacy provider of Epoprostenol for Injection

Apr 22 2010

Actelion Pharmaceuticals US, Inc., today announced that it has selected Accredo Health Group, Inc., a wholly-owned subsidiary of Medco Health Solutions, Inc., to serve as the sole specialty pharmacy provider of Epoprostenol for Injection, the only epoprostenol formulated to provide up to 24-hour stability at room temperature without the use of ice packs. This improved formulation of Epoprostenol for Injection is commercially available today in the United States for the treatment of primary pulmonary hypertension and pulmonary hypertension associated with scleroderma spectrum of disease in NYHA Class III and IV patients who do not respond adequately to conventional therapy.

"This is an exciting improvement for people with moderate to severe PAH, and we are pleased to assist patients in the administration and follow up care for this important therapy," said Accredo President Steven R. Fitzpatrick.

"We are excited to launch Epoprostenol for Injection with the Accredo team, and will leverage their coordinated patient support system and extensive experience with PAH therapies, including epoprostenol," said Shal Jacobovitz, president of Actelion Pharmaceuticals US, Inc. "This partnership will help ensure that patients have the support they need and the access to this convenient treatment option for moderate to severe PAH."

Accredo offers an enhanced level of personalized service to patients with chronic and complex disease, and will provide call center, nursing and reimbursement support services for patients using Epoprostenol for Injection and their healthcare providers. Patients and their physicians can call 1-866-FIGHTPH (1-866-344-4874), a hotline maintained by Accredo, to obtain benefit information available for Epoprostenol for Injection.